A randomized, double-blind, placebo-controlled, time-lagged, parallel-group, ascending single and multiple oral dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of LAF237 [vildagliptin] in Chinese healthy subjects

Trial Profile

A randomized, double-blind, placebo-controlled, time-lagged, parallel-group, ascending single and multiple oral dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of LAF237 [vildagliptin] in Chinese healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jun 2007 Status change from in progress to completed
    • 06 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top